Targovax ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a … Read more
Targovax ASA (0RIS) - Net Assets
Latest net assets as of June 2021: Nkr320.76 Million NOK
Based on the latest financial reports, Targovax ASA (0RIS) has net assets worth Nkr320.76 Million NOK as of June 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr459.35 Million) and total liabilities (Nkr138.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr320.76 Million |
| % of Total Assets | 69.83% |
| Annual Growth Rate | -9.77% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 23.16 |
Targovax ASA - Net Assets Trend (2017–2020)
This chart illustrates how Targovax ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Targovax ASA (2017–2020)
The table below shows the annual net assets of Targovax ASA from 2017 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | Nkr372.59 Million | +25.47% |
| 2019-12-31 | Nkr296.95 Million | -20.75% |
| 2018-12-31 | Nkr374.70 Million | -26.12% |
| 2017-12-31 | Nkr507.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Targovax ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40267000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr8.65 Million | 2.32% |
| Other Components | Nkr1.14 Billion | 306.52% |
| Total Equity | Nkr372.59 Million | 100.00% |
Targovax ASA Competitors by Market Cap
The table below lists competitors of Targovax ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT TBS Energi Utama Tbk
F:6AU
|
$16.44 Million |
|
Enzo Biochem Inc
NYSE:ENZ
|
$16.44 Million |
|
D3 Energy Ltd
AU:D3E
|
$16.46 Million |
|
Pacific Online Limited
PINK:PCOLF
|
$16.47 Million |
|
MMP Industries Limited
NSE:MMP
|
$16.42 Million |
|
Yjn Co.,Ltd.
TWO:3191
|
$16.42 Million |
|
OY Nofar Energy Ltd
TA:NOFR
|
$16.42 Million |
|
Concord Medical Services Holdings
NYSE:CCM
|
$16.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Targovax ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 296,955,000 to 372,588,000, a change of 75,633,000 (25.5%).
- Net loss of 108,126,000 reduced equity.
- Share repurchases of 176,055,000 reduced equity.
- Other factors increased equity by 359,814,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-108.13 Million | -29.02% |
| Share Repurchases | Nkr176.06 Million | -47.25% |
| Other Changes | Nkr359.81 Million | +96.57% |
| Total Change | Nkr- | 25.47% |
Book Value vs Market Value Analysis
This analysis compares Targovax ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Targovax ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17327.88%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-29.02%) is above the historical average (-35.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -24.04% | -329581.08% | 0.00x | 1.27x | Nkr-172.66 Million |
| 2018 | -39.24% | -544500.00% | 0.00x | 1.43x | Nkr-184.48 Million |
| 2019 | -49.68% | -6553.93% | 0.00x | 1.54x | Nkr-177.22 Million |
| 2020 | -29.02% | -17327.88% | 0.00x | 1.40x | Nkr-145.38 Million |
Industry Comparison
This section compares Targovax ASA's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Targovax ASA (0RIS) | Nkr320.76 Million | -24.04% | 0.43x | $16.43 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |